BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020:

SynAct Pharma AB announced that an independent Data Safety Monitoring Board has reviewed unblinded and validated data from part 1 of the company’s Phase 2a study in patients with rheumatoid arthritis with high disease activity with the aim to recommend which dose of AP1189 to be brought into part 2 of the study.

International medical imaging IT and cybersecurity company Sectra [STO: SECT B] has deployed its software for medical imaging at Leeds Teaching Hospitals.

Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women

MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, announced that it has acquired Admescope Ltd. based in Oulu, Finland and Södertälje, Sweden.

On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.

Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the U.S. Food and Drug Administration’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines.

ProMIS Neurosciences, Inc. commented on the November 6th FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting and its review of Biogen’s Biologics License Application for aducanumab for the treatment of Alzheimer’s disease.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Phase 3 CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome met its primary and key secondary endpoints at the end of Year 2.